Chad Tang, MD

Peer-Reviewed Articles

1. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, and Hoffman KE. Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study. J Urol:101097JU0000000000002902. e-Pub 2022. PMID: 36006050.
2. Sherry AD, Bathala TK, Liu S, Fellman BM, Chun SG, Jasani N, Guadagnolo BA, Jhingran A, Reddy JP, Corn PG, Shah AY, Kaiser KW, Ghia AJ, Gomez DR, Tang C. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND. Int J Radiat Oncol Biol Phys. e-Pub 2022. PMID: 35691448.
3. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive Radiotherapy for Extracranial Oligoprogressive Metastatic Renal Cell Carcinoma as a Strategy to Defer Systemic Therapy Escalation. BJU Int 129(5):610-620, 2022. e-Pub 2021. PMID: 34228889.
4. Xu C, Smith GL, Chen YS, Checka CM, Giordano SH, Kaiser K, Lowenstein LM, Ma H, Mendoza TR, Peterson SK, Shih YT, Shete S, Tang C, Volk RJ, and Sidey-Gibbons C. Short-form adaptive measure of financial toxicity from the Economic Strain and Resilience in Cancer (ENRICh) study: Derivation using modern psychometric techniques. PLoS One 17(8):e0272804, 2022. e-Pub 2022. PMID: 36006909.
5. Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio A. Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. Eur Urol 80(3):389-390, 2021. e-Pub 2021. PMID: 33824032.
6. Farooqi A, Ludmir EB, Mitchell KG, Antonoff MB, Tang C, Lee P, Chang J, Elamin Y, Gomez DR, Gandhi SJ. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. Radiother Oncol 163:114-118. e-Pub 2021. PMID: 34419505.
7. Andring L, Yoder A, Pezzi T, Tang C, Kumar R, Mahmood U, Walker GV. PSA: Declining utilization of prostate brachytherapy. Brachytherapy. e-Pub 2021. PMID: 34420862.
8. Sezen D, Verma V, He K, Abana CO, Barsoumian H, Ning MS, Tang C, Hurmuz P, Puebla-Osorio N, Chen D, Tendler I, Comeaux N, Nguyen QN, Chang JY, Welsh JW. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol 31(3):217-226, 2021. PMID: 34090648.
9. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67. e-Pub 2021. PMID: 34237343.
10. Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer 127(11):1912-1925, 2021. e-Pub 2021. PMID: 33595853.
11. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol 18(6):337-358, 2021. e-Pub 2021. PMID: 33824525.
12. Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer 22(3):225-233.e7, 2021. e-Pub 2020. PMID: 32727706.
13. Tang C, Lei X, Smith GL, Pan HY, Hoffman KE, Kumar R, Chapin BF, Shih YT, Frank SJ, Smith BD. Influence of Geography on Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys 109(5):1286-1295, 2021. e-Pub 2020. PMID: 33316361.
14. De B, Kaiser KW, Ludmir EB, Yeboa DN, Tang C, Hoffman KE, Liao Z, Koong AC, Smith BD. Radiotherapy clinical trial enrollment during the COVID-19 pandemic. Acta Oncol 60(3):1-4, 2021. e-Pub 2020. PMID: 33356801.
15. Patel RR, Verma V, Barsoumian HB, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez MA, Welsh JW. Use of Multi-Site Radiation Therapy as Systemic Therapy: A New Treatment Approach Personalized by Patient Immune Status. Int J Radiat Oncol Biol Phys 109(2):352-364, 2021. e-Pub 2020. PMID: 32798606.
16. Sanders JW, Venkatesan AM, Levitt CA, Bathala T, Kudchadker RJ, Tang C, Bruno TL, Starks C, Santiago E, Wells M, Weaver CP, Ma J, Frank SJ. Fully balanced SSFP without an endorectal coil for post-implant QA of MRI-assisted radiosurgery (MARS) of prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys 109(2):614-625, 2021. e-Pub 2020. PMID: 32980498.
17. Patel RR, Verma V, Barsoumian HB, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez MA, Welsh JW. Use of Multi-Site Radiation Therapy for Systemic Disease Control, 2021. PMID: 32798606.
18. Ranasinghe W, Shaprio DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu S, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies, 2021. PMID: 33279304.
19. Keller B, Bruynzeel AME, Tang C, Swaminath A, Kerkmeijer L, Chu W. Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma. Front Oncol 11:634830, 2021. e-Pub 2021. PMID: 34046341.
20. Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer. J Thorac Oncol 15(12):1919-1927, 2020. e-Pub 2020. PMID: 32916308.
21. Deng W, Wang Y, Liu X, Liu J, Wang L, Yang Z, Yang M, An Y, Tang C, Sanford NN, Kim BYS, Jiang W. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. JAMA Netw Open 3(12):e2028627, 2020. e-Pub 2020. PMID: 33295975.
22. Mesko S, Chapman BV, Tang C, Kudchadker RJ, Bruno TL, Sanders J, Das P, Pinnix CC, Thaker NG, Frank SJ. Development, implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents. Brachytherapy 19(6):738-745, 2020. e-Pub 2020. PMID: 32952054.
23. Frank SJ, Mourtada F, Crook J, Orio PF, Stock RG, Petereit DG, Rossi PJ, Cox BW, Tang C, Kudchadker RJ, Bruno T, Ma J, Sanders J, Keyes M. The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assurance. Brachytherapy 19(6):787-793, 2020. e-Pub 2020. PMID: 33132070.
24. Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
25. Pasalic D, Tang C, Jagsi R, Fuller CD, Koong AC, Ludmir EB. Association of Industry Sponsorship With Cancer Clinical Trial Accrual. JAMA Oncol 6(10):1625-1627, 2020. e-Pub 2020. PMID: 32815984.
26. Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer 8(2), 2020. PMID: 33051340.
27. Boyce-Fappiano D, Bathala TK, Ye R, Pasalic D, Gjyshi O, Pezzi TA, Noticewala SS, McGinnis GJ, Maroongroge S, Kuban DA, Nguyen QN, McGuire SE, Hoffman KE, Choi S, Tang C, Kudchadker RJ, Frank SJ. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy 19(5):574-583, 2020. e-Pub 2020. PMID: 32682778.
28. Pasalic D, Betancourt-Cuellar SL, Taku N, Ludmir EB, Lu Y, Allen PK, Tang C, Antonoff MB, Fuller CD, Rosenthal DI, Morrison WH, Phan J, Garden AS, Welsh JW, Chang JY, Liao Z, Erasmus JJ, Nguyen QN. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck 42(8):1939-1953, 2020. e-Pub 2020. PMID: 32129548.
29. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased frequency of Mesorectal and Perirectal LN involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys 107(5):982-985, 2020. e-Pub 2020. PMID: 32353391.
30. Crook JM, Tang C, Thames H, Blanchard P, Sanders J, Ciezki J, Keyes M, Morris WJ, Merrick G, Catton C, Raziee H, Stock R, Sullivan F, Anscher M, Millar J, Frank S. A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol 149:64-69, 2020. e-Pub 2020. PMID: 32442822.
31. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer 126(16):3667-3673, 2020. e-Pub 2020. PMID: 32453443.
32. Ning MS, Venkatesan AM, Stafford RJ, Bui TP, Carlson R, Bailard NS, Vedam S, Davis R, Olivieri ND, Guzman AB, Incalcaterra JR, McKelvey FA, Thaker NG, Rauch GM, Tang C, Frank SJ, Joyner MM, Lin LL, Jhingran A, Eifel PJ, Klopp AH. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. Brachytherapy 19(4):427-437, 2020. e-Pub 2019. PMID: 31786169.
33. Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol 10(4):282-292, 2020. e-Pub 2020. PMID: 32298794.
34. Pezzi TA, Ning MS, Thaker NG, Boyce-Fappiano D, Gjyshi O, Olivieri ND, Guzman AB, Incalcaterra JR, Mesko S, Gandhi S, Chun S, Tang C, Frank SJ, Gomez DR. Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing. Clin Transl Radiat Oncol 23:80-84, 2020. e-Pub 2020. PMID: 32529054.
35. Bathala TK, Venkatesan AM, Ma J, Bhosale P, Wei W, Kudchadker RJ, Wang J, Anscher MS, Tang C, Bruno TL, Frank SJ, Szklaruk J. Quality comparison between three-dimensional T2-weighted SPACE and two-dimensional T2-weighted turbo spin echo magnetic resonance images for the brachytherapy planning evaluation of prostate and periprostatic anatomy. Brachytherapy 19(4):484-490, 2020. e-Pub 2020. PMID: 32402544.
36. Tang C, Hoffman K, Kuban D. Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancer. Cancer 126(12):2939-2940, 2020. e-Pub 2020. PMID: 32160318.
37. Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac HA, Lu Y. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med 45(5):349-355, 2020. e-Pub 2020. PMID: 31977495.
38. Grant SR, Lei X, Hess KR, Smith GL, Matin SF, Wood CG, Nguyen Q, Frank SJ, Anscher MS, Smith BD, Karam JA, Tang C. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Adv Radiat Oncol 5(3):495-502, 2020. e-Pub 2020. PMID: 32529146.
39. Pasalic D, Lu Y, Betancourt-Cuellar SL, Taku N, Mesko SM, Bagley AF, Chance WW, Allen PK, Tang C, Antonoff MB, Balter PA, Mehran RJ, Welsh JW, Liao Z, Gomez D, Erasmus JJ, Nguyen QN. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Radiother Oncol 145:178-185, 2020. e-Pub 2020. PMID: 32044530.
40. Surasi DSS, Chapin B, Tang C, Ravizzini G, Bathala TK. Imaging and Management of Prostate Cancer. Semin Ultrasound CT MR 41(2):207-221, 2020. e-Pub 2020. PMID: 32446432.
41. Boyce-Fappiano D, Ning MS, Thaker NG, Pezzi TA, Gjyshi O, Mesko S, Anakwenze C, Olivieri ND, Guzman AB, Incalcaterra JR, Tang C, McAleer MF, Herman J, Ghia AJ. Time-Driven Activity-Based Cost Analysis of Radiation Treatment Options for Spinal Metastases. JCO Oncol Pract 16(3):JOP1900480, 2020. e-Pub 2019. PMID: 31765268.
42. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open 3(3):e201255, 2020. e-Pub 2020. PMID: 32191331.
43. Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol 15(2):266-273, 2020. e-Pub 2019. PMID: 31605794.
44. Tang C, Lee WC, Reuben A, Chang L, Tran H, Little L, Gumbs C, Wargo J, Futreal A, Liao Z, Xia X, Yi X, Swisher SG, Heymach JV, Gomez D, Zhang J. Immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC; translational correlatives from a mature randomized phase II trial. Int J Radiat Oncol Biol Phys 106(2):349-357, 2020. e-Pub 2019. PMID: 31678224.
45. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506-514, 2020. e-Pub 2019. PMID: 31742674.
46. Hanania AN, Kudchadker RJ, Bruno TL, Tang C, Anscher MS, Frank SJ. MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy. Brachytherapy 19(1):38-42, 2020. e-Pub 2019. PMID: 31812590.
47. Pasalic D, Prajapati S, Ludmir EB, Tang C, Choi S, Kudchadker R, Frank SJ. Outcomes and Toxicities of Proton and Photon Radiation Therapy for Testicular Seminoma. Int J Part Ther 7(2):11-20, 2020. e-Pub 2020. PMID: 33274253.
48. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7(12):1903-1909, 2019. e-Pub 2019. PMID: 31658994.
49. Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF. Radical Prostatectomy or Radiotherapy for High and Very High Risk Prostate Cancer: A Multidisciplinary Clinic Experience of Patients Eligible for Either Treatment. BJU Int 124(5):811-819, 2019. e-Pub 2019. PMID: 31009137.
50. Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer 7(1):237, 2019. e-Pub 2019. PMID: 31484556.
51. Ning MS, Gomez DR, Shah AK, Kim CR, Palmer MB, Thaker NG, Grosshans DR, Liao Z, Chapman BV, Brooks ED, Tang C, Rosenthal DI, Garden AS, Frank SJ, Gunn GB. The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. Int J Radiat Oncol Biol Phys 104(4):724-733, 2019. e-Pub 2018. PMID: 30557675.
52. Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, Augustyn AA, Frank SJ, Choi S, Hoffman KE, Nguyen QN, McGuire SE, Pollack A, Anscher MS. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase III, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys 104(4):790-797, 2019. e-Pub 2019. PMID: 30836166.
53. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37(18):JCO1900201, 2019. e-Pub 2019. PMID: 31067138.
54. Yu W, Tang C, Hobbs BP, Li X, Koay EJ, Wistuba II, Sepesi B, Behrens C, Rodriguez Canales J, Parra Cuentas ER, Erasmus JJ, Court LE, Chang JY. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 102(4):1090-1097, 2018. e-Pub 2017. PMID: 29246722.
55. Verma V, Cushman TR, Tang C, Welsh JW. Toxicity of radiation and immunotherapy combinations. Adv Radiat Oncol 3(4):506-511, 2018. e-Pub 2018. PMID: 30370349.
56. Sanders JW, Song H, Frank SJ, Bathala T, Venkatesan AM, Anscher M, Tang C, Bruno TL, Wei W, Ma J. Parallel imaging compressed sensing for accelerated imaging and improved signal-to-noise ratio in MRI-based postimplant dosimetry of prostate brachytherapy. Brachytherapy 17(5):816-824, 2018. e-Pub 2018. PMID: 29880449.
57. Tang C, Jiang W, Yap TA. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-Edged Sword. JAMA Oncol 4(8):1116-1117, 2018. e-Pub 2018. PMID: 29327039.
58. Verma V, Cushman TR, Selek U, Tang C, Welsh JW. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. Int J Radiat Oncol Biol Phys 101(5):1141-1148, 2018. e-Pub 2018. PMID: 30012526.
59. Kim CR, Kim B, Ning MS, Reddy JP, Liao Z, Tang C, Welsh JW, Mott FE, Shih YT, Gomez DR. Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy. Clin Lung Cancer 19(4):e517-e528, 2018. e-Pub 2018. PMID: 29685701.
60. Pan HY, Jiang J, Hoffman KE, Tang C, Choi SL, Nguyen QN, Frank SJ, Anscher MS, Shih YT, Smith BD. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol 36(18):1823-1830, 2018. e-Pub 2018. PMID: 29561693.
61. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9(48):28842-28848, 2018. e-Pub 2018. PMID: 29989021.
62. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 118(11):1419-1424, 2018. e-Pub 2018. PMID: 29695765.
63. Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep 8(1):1922, 2018. e-Pub 2018. PMID: 29386574.
64. Owens CA, Peterson CB, Tang C, Koay EJ, Yu W, Mackin DS, Li J, Salehpour MR, Fuentes DT, Court LE, Yang J. Lung tumor segmentation methods: Impact on the uncertainty of radiomics features for non-small cell lung cancer. PLoS One 13(10):e0205003, 2018. e-Pub 2018. PMID: 30286184.
65. Tang C, Lee MS, Gomez D, Levy LB, Zhuang Y, Lu C, Liao Z, Komaki R. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer. Am J Clin Oncol 40(6):625-630, 2017. e-Pub 2015. PMID: 26165417.
66. Pezzi TA, Tang C, Swanick CW, Fang P, Hess K, Xu T, Hahn SM, Chang JY, Liao Z, Gomez D. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiother Oncol 125(2):325-330, 2017. e-Pub 2017. PMID: 29054376.
67. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8(50):87163-87173, 2017. e-Pub 2017. PMID: 29152071.
68. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80-88, 2017. e-Pub 2017. PMID: 28916225.
69. Lee AS, Tang C, Hong WX, Park S, Bazalova-Carter M, Nelson G, Sanchez-Freire V, Bakerman I, Zhang W, Neofytou E, Connolly AJ, Chan CK, Graves EE, Weissman IL, Nguyen PK, Wu JC. Brief Report: External Beam Radiation Therapy for the Treatment of Human Pluripotent Stem Cell-Derived Teratomas. Stem Cells 35(8):1994-2000, 2017. e-Pub 2017. PMID: 28600830.
70. Jensen GL, Tang C, Hess KR, Liao Z, Gomez DR. Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clin Exp Metastasis 34(5):315-322, 2017. e-Pub 2017. PMID: 28744603.
71. Nguyen QN, Lu Y, Tang C, Chance WW, Mehran R, Balter P, Welsh JW, Hahn SM, Jeter MD, Komaki RU, Gomez DR, Chang JY, Liao Z. Stereotactic Ablative Body Radiation for Pulmonary Metastases: Should We Consider Dose Escalation for More Unresponsive Histologies?. Int J Radiat Oncol Biol Phys 98(1):237, 2017. PMID: 28587012.
72. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2016. PMID: 27649551.
73. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res 23(6):1407-1413, 2017. e-Pub 2016. PMID: 27852698.
74. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res 23(6):1414-1421, 2017. e-Pub 2017. PMID: 28275168.
75. Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, Welsh JW, Zhang J, Lin SH, Gomez DR. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys 97(4):770-777, 2017. e-Pub 2016. PMID: 28244413.
76. Reddy JP, Tang C, Shih T, Kim B, Kim C, Nguyen QN, Welsh J, Benveniste M, Zhang J, Liao Z, Gomez DR. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer. Clin Lung Cancer 18(2):141-148, 2017. e-Pub 2016. PMID: 27913215.
77. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res 77(4):839-850, 2017. e-Pub 2016. PMID: 27821490.
78. Tang C, Welsh JW, Hong D. Phase I Trial: SABR and Ipilimumab-Response. Clin Cancer Res 23(1):321, 2017. PMID: 28049161.
79. Jensen G, Tang C, Hess KR, Bishop AJ, Pan HY, Li J, Yang JN, Tannir NM, Amini B, Tatsui C, Rhines L, Brown PD, Ghia AJ. Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery. J Radiosurg SBRT 5(1):25-34, 2017. PMID: 29296460.
80. Abou Yehia Z, Mikhaeel GN, Smith G, Pinnix CC, Milgrom SA, Tang C, Jiang W, Fanale MA, Oki Y, Shank JH, Horace T, Reddy J, Akhtari M, Gunther JR, Suki T, Allen PK, Turner S, Mawlawi O, Dabaja BS. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. Int J Radiat Oncol Biol Phys 96(5):951-958, 2016. e-Pub 2016. PMID: 27742539.
81. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672-1682, 2016. e-Pub 2016. PMID: 27789196.
82. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep 6:35448, 2016. e-Pub 2016. PMID: 27748430.
83. Ho JC, Tang C, Deegan BJ, Allen PK, Jonasch E, Amini B, Wang XA, Li J, Tatsui CE, Rhines LD, Brown PD, Ghia AJ. The use of spine stereotactic radiosurgery for oligometastatic disease. J Neurosurg Spine 25(2):239-47, 2016. e-Pub 2016. PMID: 27035507.
84. Tang C, Liao Z, Hess K, Chance WW, Zhuang Y, Jensen G, Xu T, Komaki R, Gomez DR. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta Oncol 55(8):1022-8, 2016. e-Pub 2016. PMID: 27055359.
85. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget 7(34):54627-54631, 2016. PMID: 27421137.
86. Jiang W, Mohamed ASR, Fuller CD, Kim BYS, Tang C, Gunn GB, Hanna EY, Frank SJ, Su SY, Diaz E, Kupferman ME, Beadle BM, Morrison WH, Skinner H, Lai SY, El-Naggar AK, DeMonte F, Rosenthal DI, Garden AS, Phan J. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol 6(4):241-7, 2016. e-Pub 2015. PMID: 26979544.
87. Tang C, Hess K, Bishop AJ, Pan HY, Christensen EN, Yang JN, Tannir N, Amini B, Tatsui C, Rhines L, Brown P, Ghia A. Creation of a Prognostic Index for Spine Metastasis to Stratify Survival in Patients Treated With Spinal Stereotactic Radiosurgery: Secondary Analysis of Mature Prospective Trials. Int J Radiat Oncol Biol Phys 93(1):118-25, 2015. e-Pub 2015. PMID: 26130231.
88. Grant JD, Jensen GL, Tang C, Pollard JM, Kry SF, Krishnan S, Dougherty AH, Gomez DR, Rozner MA. Radiotherapy-Induced Malfunction in Contemporary Cardiovascular Implantable Electronic Devices: Clinical Incidence and Predictors. JAMA Oncol 1(5):624-32, 2015. PMID: 26181143.
89. Grant JD, Shirvani SM, Tang C, Juloori A, Rebueno NC, Allen PK, Chang JY. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. Pract Radiat Oncol 5(4):e383-91, 2015. e-Pub 2015. PMID: 25731965.
90. Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, Eyben RV, Hara WY, Trakul N, Loo Jr BW, Diehn M. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors, 2015. PMID: 25997421.
91. Huang AT, Tang C, Bell D, Yener M, Izquierdo L, Frank SJ, El-Naggar AK, Hanna EY, Weber RS, Kupferman ME. Prognostic factors in adenocarcinoma of the salivary glands. Oral Oncol 51(6):610-5, 2015. e-Pub 2015. PMID: 25843792.
92. Tang C, Chan C, Jiang W, Murphy JD, Eyben RV, Colevas AD, Pinto H, Lee-Enriquez N, Kong C, Le Q. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer, 2015. PMID: 24431011.
93. Wasterlain AS, Tran AA, Tang C, Campbell DR, Braun HJ, Scuderi YA, Scuderi GJ. Can We Improve Workflows in the OR? A Comparison of Quality Perceptions and Preoperative Efficiency across Institutions in Spine Surgery, 2015. PMID: 26517001.
94. Tang C, Fuller CD, Garden AS, Awan MJ, Colen RR, Morrison WH, Frank SJ, Beadle BM, Phan J, Sturgis EM, Zafereo ME, Weber RS, Rosenthal DI, Gunn GB. Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response. Oral Oncol 51(2):195-201, 2015. e-Pub 2014. PMID: 25444304.
95. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer 13(1):e19-26, 2015. e-Pub 2014. PMID: 25087088.
96. Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 91(1):149-56, 2015. e-Pub 2014. PMID: 25442335.
97. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res 20(23):5956-63, 2014. e-Pub 2014. PMID: 25316815.
98. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res 20(24):6336-45, 2014. e-Pub 2014. PMID: 25326232.
99. de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer 14(6):468-74, 2014. e-Pub 2014. PMID: 25065564.
100. Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 89(5):1084-91, 2014. e-Pub 2014. PMID: 25035212.
101. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget 5(7):1837-45, 2014. PMID: 24742823.
102. Tang C, Liao Z, Zhuang Y, Levy LB, Hung C, Li X, Krafft SP, Martel MK, Komaki R, Gomez DR. Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiother Oncol 110(3):493-8, 2014. e-Pub 2014. PMID: 24560756.
103. Tang C, Gomez DR, Wang H, Levy LB, Zhuang Y, Xu T, Nguyen Q, Komaki R, Liao Z. Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88(2):319-25, 2014. PMID: 24411603.
104. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience 1(1):5-13, 2014. e-Pub 2013. PMID: 25593979.
105. Fontes Jardim DL, Tang C, De Melo-Gagliato D, Falchook GS, Hess KR, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla VR, Li MM, Roy Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Berstein F, Hong D. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson phase I clinic. Clin Cancer Res 20(24):6335-45 *Equal contributions, 2014.
106. Tang C, Komakula S, Chan C, Murphy JD, Jiang W, Kong C, Lee-Enriquez N, Jensen KC, Fischbein NJ, Le Q. Radiologic assessment of retropharyngeal node involvement in oropharyngeal carcinomas stratified by HPV status, 2013. PMID: 24103114.
107. Chung MP, Tang C, Chan C, Hara WY, Loo BW, Kaplan MJ, Fischbein N, Le QT, Chang DT. Radiotherapy for nonadenoid cystic carcinomas of major salivary glands. Am J Otolaryngol 34(5):425-30, 2013. e-Pub 2013. PMID: 23583094.
108. Tang C, Fischbein NJ, Murphy JD, Chu KP, Bavan B, Dieterich S, Hara W, Kaplan MJ, Colevas AD, Le QT. Stereotactic radiosurgery for retreatment of gross perineural invasion in recurrent cutaneous squamous cell carcinoma of the head and neck. Am J Clin Oncol 36(3):293-8, 2013. PMID: 22547009.
109. Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, Colevas AD, Iagaru AH, Graves EE, Loo BW, Le QT. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys 83(5):1514-20, 2012. e-Pub 2012. PMID: 22270174.
110. Drukker M, Tang C, Ardehali R, Rinkevich Y, Seita J, Lee AS, Mosley AR, Weissman IL, Soen Y. Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells. Nat Biotechnol 30(6):531-42, 2012. e-Pub 2012. PMID: 22634564.
111. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109(17):6662-7, 2012. e-Pub 2012. PMID: 22451913.
112. Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, Willingham SB, Pazhanisamy SK, Contreras-Trujillo H, Storm TA, Lotan Y, Beck AH, Chung BI, Alizadeh AA, Godoy G, Lerner SP, van de Rijn M, Shortliffe LD, Weissman IL, Chan KS. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A 109(6):2078-83, 2012. e-Pub 2012. PMID: 22308455.
113. Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118(18):4890-901, 2011. e-Pub 2011. PMID: 21828138.
114. Tang C, Drukker M. Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations, 2011. PMID: 21479877.
115. Tang C, Lee AS, Volkmer JP, Sahoo D, Nag D, Mosley AR, Inlay MA, Ardehali R, Chavez SL, Pera RR, Behr B, Wu JC, Weissman IL, Drukker M. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 29(9):829-34, 2011. e-Pub 2011. PMID: 21841799.
116. Ardehali R, Inlay MA, Ali SR, Tang C, Drukker M, Weissman IL. Overexpression of BCL2 enhances survival of human embryonic stem cells during stress and obviates the requirement for serum factors. Proc Natl Acad Sci U S A 108(8):3282-7, 2011. e-Pub 2011. PMID: 21300885.
117. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71(4):1374-84, 2011. e-Pub 2010. PMID: 21177380.
118. Behr B, Tang C, Germann G, Longaker MT, Quarto N. Locally applied vascular endothelial growth factor A increases the osteogenic healing capacity of human adipose-derived stem cells by promoting osteogenic and endothelial differentiation, 2011. PMID: 21732486.
119. Lu WJ, Lan F, He Q, Lee A, Tang C, Dong L, Lan B, Ma X, Wu JC, Shen L. Inducible expression of stem cell associated intermediate filament nestin reveals an important role in glioblastoma carcinogenesis, 2011. PMID: 20669222.
120. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5):699-713, 2010. PMID: 20813259.
121. Lee AS, Tang C, Cao F, Xie X, van der Bogt K, Hwang A, Connolly AJ, Robbins RC, Wu JC. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 8(16):2608-12, 2009. e-Pub 2009. PMID: 19597339.
122. Tang C, Kligman F, Larsen CC, Kottke-Marchant K, Marchant RE. Platelet and endothelial adhesion on fluorosurfactant polymers designed for vascular graft modification. J Biomed Mater Res A 88(2):348-58, 2009. PMID: 18286624.
123. Zhu J, Tang C, Kottke-Marchant K, Marchant RE. Design and synthesis of biomimetic hydrogel scaffolds with controlled organization of cyclic RGD peptides. Bioconjugate Chemistry, 2009. PMID: 19191566.
124. Larsen CC, Kligman F, Tang C, Kottke-Marchant K, Marchant RE. A biomimetic peptide fluorosurfactant polymer for endothelialization of ePTFE with limited platelet adhesion. Biomaterials 28(24):3537-48, 2007. e-Pub 2007. PMID: 17507089.
125. Tang C, Sula MJ, Bohnet S, Rehman A, Taishi P, Krueger JM. Interleukin-1beta induces CREB-binding protein (CBP) mRNA in brain and the sequencing of rat CBP. Brain Res Mol Brain Res 137(1-2):213-22, 2005. e-Pub 2005. PMID: 15950780.

Invited Articles

1. Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 16(2):81-104, 2019. e-Pub 2018. PMID: 30356138.
2. Tang C, Chang JY. PD-L1 expression in lung cancer. J Thorac Dis 8(11):3053-3055, 2016. PMID: 28066581.
3. Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J 22(4):257-66, 2016. PMID: 27441745.
4. Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J 22(2):130-7, 2016. PMID: 27111909.
5. Seyedin SN, Tang C, Welsh JW. Author's view: radiation and immunotherapy as systemic therapy for solid tumors. Oncoimmunology 4(3):e986402, 2015. e-Pub 2015. PMID: 25949899.
6. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-980, 2015. e-Pub 2015. PMID: 26310908.
7. Jiang W, Tang C, Chang J. Radiation with immunotherapy: an emerging combination for cancer treatment. Journal of Radiation Oncology 4:331-8, 2015.
8. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. Cancer Immunol Res 2(9):831-8, 2014. PMID: 25187273.
9. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl Lung Cancer Res 3(1):53-63, 2014. PMID: 25806281.
10. Tang C, Jardim DL, Hong D. MET in ovarian cancer: metastasis and resistance?. Cell Cycle 13(8):1220-1, 2014. e-Pub 2014. PMID: 24621499.
11. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 19(8):998-1004, 2013. e-Pub 2013. PMID: 23921754.
12. Tang C, Weissman IL, Drukker M. The safety of embryonic stem cell therapy relies on teratoma removal. Oncotarget 3(1):7-8, 2012. PMID: 22294556.

Editorials

1. Tang C, Welsh JW, Hong DS. Reply to Hiniker et al. Clinical Cancer Research, 2017.

Book Chapters

1. Tang C, Cortez MA, Hong D, Welsh JW. Targeting the c-Met kinase. In: Targeted Therapy in Translational Cancer Research, 343-8, 2015.
2. Tang C, Weissman IL, Drukker M. Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives. In: Methods Molecular Biology, 17-31, 2013.

Books (edited and written)

1. Wolters Kluwer. Pocket Oncology: The MD Anderson Handbook of Radiation Oncology. Ed(s) Chad Tang and Ahsan Farooqi, 2019.